A phase III, double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy and safety of Ravulizumab

A phase III, double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy and safety of Ravulizumab administered intravenously in adult participants at high risk of delayed graft function after kidney transplantation.

Abierta

Código protocolo: ALXN1210-DGF-321
Código EudraCT: _
Grupo de investigación: Nefrología y Trasplante Renal
Servicio: Nefrología
Investigador/a principal: Moreso Mateos, Francesc
Patología: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
Fase: Fase III